Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Has Average Target Price of $16.20 According to Brokerages

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has received an average recommendation of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $17.00.

XERS has been the topic of a number of analyst reports. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a research note on Wednesday, November 4th. Oppenheimer restated an “outperform” rating and issued a $21.00 target price (up from $18.00) on shares of Xeris Biopharma in a report on Friday, November 6th. Leerink Partners upped their target price on Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a research report on Thursday, September 10th. Finally, HC Wainwright increased their price target on Xeris Biopharma from $10.00 to $18.00 and gave the company a “buy” rating in a report on Friday, November 6th.

Insider Transactions at Xeris Biopharma

In related news, insider Steven Pieper sold 5,000 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total transaction of $51,150.00. Following the completion of the sale, the insider directly owned 1,346,053 shares of the company’s stock, valued at approximately $13,770,122.19. This represents a 0.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 25,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total transaction of $255,750.00. Following the completion of the transaction, the insider owned 1,086,130 shares in the company, valued at $11,111,109.90. The trade was a 2.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 168,332 shares of company stock worth $1,678,971. 4.35% of the stock is owned by insiders.

Hedge Funds Weigh In On Xeris Biopharma

Several large investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in Xeris Biopharma during the 2nd quarter valued at $115,042,000. Legal & General Group Plc acquired a new stake in Xeris Biopharma in the 2nd quarter worth $15,941,000. Parkman Healthcare Partners LLC acquired a new stake in Xeris Biopharma in the 2nd quarter worth $14,316,000. Bank of America Corp DE acquired a new stake in Xeris Biopharma in the 2nd quarter worth $11,065,000. Finally, Vilga Financial Planning LLC acquired a new stake in Xeris Biopharma in the 3rd quarter worth $10,134,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Stock Up 0.1%

NASDAQ:XERS traded up $0.01 during trading hours on Tuesday, reaching $16.66. The company’s stock had a trading volume of 3,399,051 shares, compared to its average volume of 3,410,190. The company has a market cap of $3.04 billion, a price-to-earnings ratio of -333.13 and a beta of 0.61. Xeris Biopharma has a one year low of $5.25 and a one year high of $16.88. The business’s 50-day moving average is $10.40 and its 200-day moving average is $7.84. The company has a debt-to-equity ratio of 3.89, a current ratio of 2.15 and a quick ratio of 1.02.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, November 5th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a negative net margin of 1.76% and a positive return on equity of 147.75%. The firm had revenue of $107.23 million for the quarter, compared to the consensus estimate of $101.68 million. Equities research analysts predict that Xeris Biopharma will post 0.15 EPS for the current year.

About Xeris Biopharma

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative. The company also develops drug-delivery technologies intended to make medicines easier to store and administer.